EpiMag 96-Well Viral RNA Extraction Kit (High Throughput)

Product Description

• High throughput and fast: Total RNA from 96 samples simultaneously within 30 minutes
• Allows small size (>200 bases) and large size (<200 kb) to be isolated
• Convenient handling without the need for centrifugation
• Suitable for robotic handling or automation setup
• Ready-to-use RNA for high performance in downstream application
• Consistent RNA yield from a small amount of starting material

The EpiMag™ 96-Well Viral RNA Extraction Kit (High Throughput) is a complete set of optimized buffers and reagents that is suitable for quick preparation of viral RNA in a high throughput manner with magnetic beads from cell-free liquid specimens, specifically from saliva and nasal or nasopharyngeal swabs. The specialized buffering system allows RNA to bind to the magnetic beads while contaminants and impurities are efficiently washed away, and pure RNA is eluted.

Principle & Procedure

The kit contains all the reagents required for successfully performing RNA isolation directly from cell-free samples. After lysis, binding, and wash, RNA is easily recovered in quantities of up to 2 µg using specially designed magnetic beads. Total RNA is then ready to be used for a variety of downstream applications.

Starting Materials

The amount of starting materials can be 135 µl. A total of 96 standard extractions can be performed with this kit.

Performance Data

Fig.1. Quantification analysis of the isolated RNA. RNA fragment at different concentrations was spiked into normal saline and then isolated with the EpiMag 96-Well Viral RNA Extraction Kit (High Throughput). Isolated RNA was then fluorescently quantified using a fluorescent method for RNA/ssDNA measurement.

Fig.2. Total RNA was isolated from nasal swab and saliva samples with EpiMag 96-Well Viral RNA Extraction Kit (High Throughput) and was used for RT-PCR analysis. A: nasal swab sample was spiked with SARS-CoV-2-N positive control; B: nasal swab sample was not spiked with SARS-CoV-2-N positive control. C: saliva sample was spiked with SARS-CoV-2-N positive control; D: Saliva sample was not spiked with SARS-CoV-2-N positive control. PCR was processed with the use of primers and probes against SARS-CoV-2 N1, SARS-CoV-2 N2, and human RNase P gene (internal control).